Literature DB >> 19917246

A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation.

Michael Stilmann1, Michael Hinz, Seda Cöl Arslan, Anja Zimmer, Valérie Schreiber, Claus Scheidereit.   

Abstract

Upon genotoxic stresses, cells activate IkappaB kinases (IKKs) and the transcription factor NF-kappaB to modulate apoptotic responses. The SUMO-1 ligase PIASy and the kinase ataxia talengiectasia mutated (ATM) have been implicated to SUMOylate and phosphorylate nuclear IKKgamma (NEMO) in a consecutive mode of action, which in turn results in activation of cytoplasmic IKK holocomplexes. However, the nuclear signals and scaffold structures that initiate IKKgamma recruitment and activation are unknown. Here, we show that poly(ADP-ribose)-polymerase-1 (PARP-1) is the DNA proximal regulator, which senses DNA strand breaks and, through poly(ADP-ribose) (PAR) synthesis, assembles IKKgamma, PIASy, and ATM in a dynamic manner. Signalosome formation involves direct protein-protein interactions and binding to ADP-ribose polymers through PAR binding motifs (PARBM). Activated PARP-1 and a PARBM in PIASy are required to trigger IKKgamma SUMOylation, which in turn permits IKK and NF-kappaB activation, as well as NF-kappaB-regulated resistance to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917246     DOI: 10.1016/j.molcel.2009.09.032

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  113 in total

1.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

2.  An additional long-term mechanism of NF-κB regulation after cytokine treatment in a human hepatoma cell line.

Authors:  Patricia Kohlhof
Journal:  Virchows Arch       Date:  2010-09-23       Impact factor: 4.064

Review 3.  The DNA damage-induced cell death response: a roadmap to kill cancer cells.

Authors:  Sonja Matt; Thomas G Hofmann
Journal:  Cell Mol Life Sci       Date:  2016-01-20       Impact factor: 9.261

4.  The region of XRCC1 which harbours the three most common nonsynonymous polymorphic variants, is essential for the scaffolding function of XRCC1.

Authors:  Audun Hanssen-Bauer; Karin Solvang-Garten; Karin Margaretha Gilljam; Kathrin Torseth; David M Wilson; Mansour Akbari; Marit Otterlei
Journal:  DNA Repair (Amst)       Date:  2012-01-26

Review 5.  Nuclear initiated NF-κB signaling: NEMO and ATM take center stage.

Authors:  Shigeki Miyamoto
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

6.  PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.

Authors:  Jennifer Stanley; Lisa Klepczyk; Kimberly Keene; Shi Wei; Yufeng Li; Andres Forero; William Grizzle; Monica Wielgos; Jason Brazelton; Albert F LoBuglio; Eddy S Yang
Journal:  Breast Cancer Res Treat       Date:  2015-04-02       Impact factor: 4.872

7.  Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor-κB Activation.

Authors:  Wei Wang; Bo Zhang; Arul M Mani; Zhongzhi Wu; Yu Fan; Wei Li; Zhao-Hui Wu
Journal:  J Pharmacol Exp Ther       Date:  2018-05-07       Impact factor: 4.030

Review 8.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

Review 9.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

10.  The DNA damage response induces IFN.

Authors:  Sabrina Brzostek-Racine; Chris Gordon; Sarah Van Scoy; Nancy C Reich
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.